Loading...
•
Mar 31, 2024
Editas Q1 2024 Earnings Report
Editas reported first quarter results with progress in clinical trials and strategic collaborations.
Key Takeaways
Editas Medicine reported a net loss of $62.0 million for the first quarter of 2024, with advancements in their reni-cel program and in vivo medicine development. They have a strong financial position with an operational runway into 2026.
Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease.
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel for transfusion-dependent beta-thalassemia in mid-2024 and additional updates by year-end 2024.
Presented pre-clinical data at ASGCT on in vivo capabilities to support development of transformative in vivo gene editing medicines.
Cash, cash equivalents, and marketable securities as of March 31, 2024, were $376.8 million, expected to fund operations into 2026.
Revenue by Segment
Forward Guidance
Editas Medicine anticipates presenting clinical data from the RUBY and EdiTHAL trials in mid-2024 and year-end 2024 and expects existing cash to fund operations into 2026.
Positive Outlook
- On track to present additional clinical data from the RUBY trial in mid-2024.
- On track to present additional clinical data from the EdiTHAL trial in mid-2024.
- Anticipate additional data updates from RUBY trial by year-end 2024.
- Anticipate additional data updates from EdiTHAL trial by year-end 2024.
- Expects existing cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditures into 2026.
Challenges Ahead
- Uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials.
- Availability and timing of results from pre-clinical studies and clinical trials is uncertain.
- Interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...